Earnings call transcript: Recordati Q1 2026 sees revenue growth, stock rises 3.39%

Recordati delivered a solid Q1 2026 beat, with revenue up 4.9% to €730 million, EBITDA up 5.0% to €284 million, and adjusted net income up 7.2% to €188 million; EBITDA margin held at 39.7%. Rare disease revenue rose 14.8%, led by ISTURISA and Enjaymo, while the company maintained full-year 2026 guidance of €2.73 billion-€2.80 billion in revenue and €995 million-€1.03 billion of EBITDA despite a 4.3% FX drag. Shares rose 3.39% after the announcement, and management said U.S. tariff risk is currently contained for 2026.

Analysis

The key signal here is not simply “good quarter,” but that Recordati is converting rare-disease commercialization into a self-reinforcing operating model: U.S. field expansion is front-loading SG&A now, while the revenue uplift should compound into 2H and into 2027 as new prescribers move from first scripts to repeat usage. That creates a near-term margin drag that is strategically positive, and the market may be underestimating how much of the incremental spend is aimed at expanding the addressable diagnosis pool rather than just defending share.

The second-order winner is anyone with exposure to specialty pharma monetization in the U.S. reimbursement channel: better patient enrollment trends, even before active scripts fully catch up, suggest demand is already there and the bottleneck is administrative conversion, not clinical adoption. That is important because it implies the growth runway is less sensitive to short-term macro or seasonal noise than the headline mix suggests. On the flip side, the weaker SPC segment and Germany tender discipline are deliberate portfolio pruning, not deterioration; this usually looks ugly in the quarter but improves long-run quality, so peers chasing volume at any price may actually look worse on relative margin stability.

The main risk is timing mismatch: if the U.S. conversion funnel takes longer than expected, the market could temporarily punish the higher expense base before the embedded 2H uplift shows up. FX remains the clearest external swing factor, but the company is already signaling that currency is a numerator issue, not a thesis breaker. The bigger contrarian point is that the PBH and ITP pipeline options are probably being modeled too conservatively by the street; the market tends to discount rare-disease pipeline probability too aggressively until pivotal design is clarified, so any FDA update in the next 1-2 quarters could re-rate the stock faster than the cash flow story alone.

Net: this is a quality compounder with a near-term spend spike that likely pays back over 6-12 months. The stock’s post-earnings move looks directionally right, but the deeper rerating should come only if management proves that U.S. patient conversion continues to accelerate through Q2/Q3 while pipeline execution removes one more layer of discount.

Key Decisions for Investors

• Buy 0KBS on 2-3% pullbacks over the next 2-4 weeks; risk/reward favors adding before the Q2 inflection, with upside to a higher multiple if U.S. enrollment converts into active patients as guided.
• Pair trade: long 0KBS / short a slower-growing European healthcare peer with less U.S. rare-disease exposure over 3-6 months; thesis is better mix + stronger conversion funnel should outperform on both growth and margin durability.
• Use a call spread on 0KBS for a 6-9 month horizon (e.g., 55/60 or nearest available strikes) to express the view that the market is underpricing 2H acceleration while capping premium outlay if FX or conversion stalls.
• Avoid chasing after the initial earnings pop; wait for the next operating datapoint on prescriber conversion or enrollment-to-script conversion, because the main downside catalyst is a temporary miss versus heightened expectations in Q2.
• Watch for a catalyst trade around FDA/PBH updates in the next 1-2 quarters; if management provides a clearer pivotal path, add tactically on that event because pipeline optionality is not fully reflected in the current setup.